SCHEMBL1590600

SCHEMBL1590600

Cc1ccccc1CC(=O)Nc1cccc2c(=O)n(C(O)C3CCCCC3)ccc12

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 7/20 0.44
SMN1; SMN2 Q16637 4/20 0.41
ALDH1A1 P00352 4/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
SHMT2 P34897 1/20 0.39
KDM4E B2RXH2 1/20 0.39
POLB P06746 1/20 0.39
HPGD P15428 1/20 0.39
HSD17B10 Q99714 1/20 0.39
LMNA P02545 2/20 0.38
TSHR P16473 1/20 0.38
HTT P42858 1/20 0.38
ALPL P05186 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1590635 0.92 P2RX7 (0.43) P2RX7SMN1; SMN2ALDH1A1SHMT2KDM4E
SCHEMBL1590869 0.90 PARP14 (0.44) P2RX7ALDH1A1KMT2AKDM4EPOLB
SCHEMBL1591502 0.90 KMT2A (0.47) P2RX7SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL1591762 0.89 KMT2A (0.47) P2RX7ALDH1A1MEN1KMT2AKDM4E
SCHEMBL1591354 0.89 KCNQ2 (0.47) P2RX7ALDH1A1KDM4ETSHR
SCHEMBL1591055 0.88 LMNA (0.51) P2RX7SMN1; SMN2ALDH1A1KMT2AKDM4E
SCHEMBL1591015 0.87 P2RX7 (0.43) P2RX7SMN1; SMN2ALDH1A1SHMT2KDM4E
SCHEMBL1589957 0.87 P2RX7 (0.47) P2RX7SMN1; SMN2ALDH1A1KDM4EHPGD
SCHEMBL1591062 0.87 TSHR (0.47) P2RX7SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL1590341 0.86 P2RX7 (0.46) P2RX7SMN1; SMN2ALDH1A1SHMT2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110092476-A1 Bicycloheteroaryl compounds as P2X7 modulators and uses thereof RENOVIS, INC. 2011-04-21 US claimed
US-7816371-B2 Bicycloheteroaryl compounds as P2X7 modulators and uses thereof RENOVIS, INC. (US) 2010-10-19 US claimed
US-20070225324-A1 Bicycloheteroaryl compounds as P2X7 modulators and uses thereof SECOND GENOME, INC. 2007-09-27 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225324-A1 Bicycloheteroaryl compounds as P2X7 modulators and uses thereof P2RX7, P2RX3, P2RX2 P2RX7 1/4885SMN1; SMN2 4369/4885ALDH1A1 3640/4885
US-20110092476-A1 Bicycloheteroaryl compounds as P2X7 modulators and uses thereof P2RX7, P2RX3, P2RX2 P2RX7 1/4885SMN1; SMN2 4369/4885ALDH1A1 3640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.